Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2009
06/23/2009US7550597 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
06/23/2009US7550595 Bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethylpiperidin-4-yl ester; dosage forms such as metered dose inhalers
06/23/2009US7550593 Dissolving finasteride in a solvent, replacing the solvent partially or substantially completely with a non-solvent and thereafter isolating finasteride Form I; 5-alpha reductase inhibitor, for example in the treatment of acne vulgaris, seborrhea, female hirsutism, androgenic alopecia
06/23/2009US7550590 Such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile; type 2 diabetes mellitus, diabetic dislipidemia, impaired glucose tolerance
06/23/2009US7550587 Photosensitizer and method for production thereof
06/23/2009US7550584 Methods of purifying beta glucans
06/23/2009US7550580 heat shock protein 27 inhibitors; RNA interference; nuclease resistance
06/23/2009US7550511 amino alcohols; selective ribonucleic acid (RNA) binding agents; detecting the binding of small molecules to T-box antiterminator model mRNAs; screening for microbiocidal drug targets; use disinfecting; antiviral, anti-HIV; e.g. use of 1,2-dihydroxy-3-amino-4-phenylbutane
06/23/2009US7550510 Reacting hexachloroacetone with solvent-suspended resin-bound triphenylphosphine, chlorinating retinoic acid to provide retinoyl chloride, then stirring in pyridine; chromatography; for induction of apoptosis in cancer cells
06/23/2009US7550509 Carisoprodol articles and methods
06/23/2009US7550508 Prostaglandin analog compositions and methods to treat epithelial-related conditions
06/23/2009US7550507 2-(alpha-hydroxypentyl) benzoate and its preparation and use
06/23/2009US7550506 Amino acid derived prodrugs of propofol, compositions and uses thereof
06/23/2009US7550505 Such as N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methyl-3-(naphthalen-1-ylsulfonyl)propanamide; acne, seborrhea, hirsutism, alopecia, hidradenitis suppurativa; prostate cancer
06/23/2009US7550504 In particular, butyrates and formates of divalent metals, as well as their carboxylate-aminoate or carboxylate-methioninate hydroxy analog derivatives of divalent metals; use as trace metal supplements in animal feed; increasing bioavailability of metals, therefore reducing their emission to environment
06/23/2009US7550503 Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy
06/23/2009US7550502 e.g. 5-[(R)-1-(4-tert-Butyl-phenyl)-5-oxo-pyrrolidin-2-ylmethoxy]-pentanoic acid; prostaglandin EP2 agonist; ocular hypotensive, antiinflammatory agent; glaucoma, inflammatory bowel disease and as presurgical adjuncts
06/23/2009US7550501 Compounds and methods for treating toll-like receptor 2-related diseases and conditions
06/23/2009US7550500 Bicyclic and tricyclic amines as modulators of chemokine receptor activity
06/23/2009US7550499 Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
06/23/2009US7550498 Antiinflammatory agents, analgesics; e.g. Dimethyl-(2-[2-(8-thia-1,2-diaza-dibenzo[e,h]azulene-1-yl)-ethoxy]-ethyl)-amine and chemical intermediates; treating TNF-related disorders such as rheumatoid arthritis
06/23/2009US7550497 sulfonamidophosphonate-functional heteroaryl compounds that contain SO2-NH-P(O)(-OR)2 group; antiinflammatory and analgesics; e.g. N-[4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl]phenylsulfonyl]phosphoramidic acid; injectable COX-2 inhibitors
06/23/2009US7550496 Hypoxia-activated prodrugs of alkylating agents such as of cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa; protected with 2-nitroimidazolyl group; targeted cancer cells more effectively, side effect reduction
06/23/2009US7550495 1-(4,4-difluorocyclohexylmethyl)-2-tert-butyl-5-ethylsulfonamido-1H-benzimidazole; pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and/or cardiovascular disorders; CB1 receptor agonists; side effect reduction
06/23/2009US7550494 Small molecules useful in the treatment of inflammatory disease
06/23/2009US7550493 Halogenated benzamide derivatives
06/23/2009US7550492 Cholecystokinin (CCK2) receptor modulators; e.g. 2-(Benzo[1,2,5]thiadiazole-4sulfonylamino)-4-fluoro-N-[1-(4-fluoro-phenyl)-ethyl]-N-methyl-benzamide; pancreatic adenocarcinoma, pain, eating disorders, gastro-esophageal reflux disease, ulcers, anxiety
06/23/2009US7550491 Ionic liquids having [N(CF3)2]− anions
06/23/2009US7550490 Cancer and psoriasis; e.g. N-(2-amino-4-fluorophenyl)-4-[N-(Pyridin-3-ylacryloyl)aminomethyl]benzamide
06/23/2009US7550489 N-[3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide and phentermine, metformin, or bupropion; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
06/23/2009US7550488 Treating a patient suffering from facial submandibular cellulitis by applying a topical agent comprising 5 wt. % vitamin B5 and 30 wt. % vitamin B6 in a carrier selected from dimethyl sulfoxide and soy lecithin in combination with orally administering an antibiotic
06/23/2009US7550487 Factor Xa inhibitors; anticoagulants; thrombotic disorders; (3R,4R)-3-(4-Chloro-phenylcarbamoyl)-4-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-pyrrolidine-1-carboxylic acid propyl ester for example
06/23/2009US7550486 chemokine receptor (CCR) inhibitors for treating allergic or inflammatory diseases such as asthma or rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases; 2-((p-fluorobenzyl)piperidinylmethyl)cyclohexylureas of given formula
06/23/2009US7550485 Conditions ameliorated by monoamine reuptake such as hot flashes, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; e.g. 1-[2-(1,4'-bipiperidin-1'-yl)-1-(3-chlorophenyl)ethyl]cyclohexanol dihydrochloride
06/23/2009US7550484 Elevate the progenitor and/or stem cell population in peripheral blood or bone marrow; treatment of HIV, inflammatory condition like rheumatoid arthritis, tumor, asthma; 4-(3,3''-Dimethyl-3',4',5',6'-tetrahydro-2'H-cis-[2,2';6',2'']terpyridin-1'-yl-butylamine
06/23/2009US7550483 High usability as medicaments; useful as an angiogenesis inhibitor or a c-Kit kinase inhibitor; prepared by dissolving a crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate in an alcohol and water
06/23/2009US7550482 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
06/23/2009US7550481 Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of Alzheimer's disease
06/23/2009US7550480 1,8-naphthyridin-2(1H)-ones; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs
06/23/2009US7550479 Modified Pictet-Spengler reaction and products prepared therefrom
06/23/2009US7550478 Tyrosine kinase inhibitors
06/23/2009US7550477 Anticancer agents; initiasting mitosis which causes tumor cell death
06/23/2009US7550476 Condensed polycyclic compounds
06/23/2009US7550475 Use of phosphodiesterase 4 inhibitors such as 6,7-dimethoxy-1-[2-(1,3-dioxocyclohexan-2-yl)pyridin-4-yl]-2,3-bis(hydroxymethyl)naphthalene to treat asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis
06/23/2009US7550474 Anticoagulants; strokes; restenosis; antiinflamamtory agents
06/23/2009US7550473 Pyrimidine derivatives useful as inhibitors of PKC-theta
06/23/2009US7550472 Substituted pteridines for the treatment of inflammatory diseases
06/23/2009US7550471 5-alkyl-7-aminotriazolopyrimidines, methods and intermediary product necessary for the production thereof, agents containing said compounds and the use thereof for fighting against harmful mushrooms
06/23/2009US7550470 Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
06/23/2009US7550469 Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
06/23/2009US7550468 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase
06/23/2009US7550467 1-(3-chloro-4-fluorophenyl)-3-(7-acetamidotetralin-2-yl)-3-(3-(4-methylpiperazinyl)propyl)-urea for example
06/23/2009US7550466 Alpha and/or β-adrenergic antagonists and agonists to treat pain
06/23/2009US7550465 imidazo[1,5-a]pyrido[3,2-e]pyrazines; neurologic and psychiatric disorders, for example psychosis
06/23/2009US7550464 Use of phosphodiesterase 4 inhibitors such as 8,9-dimethoxy-6-phenyl-1,3,4,6,11,11a-hexahydro-2H -pyrazino[1,2-b]isoquinoline for treating asthma, chronic obstructive pulmonary disease, atopic dermatitis, allergic rhinitis, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis
06/23/2009US7550463 Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
06/23/2009US7550462 3-(2,3-dihydro-1H-inden-2-yl)-1-[1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[1-methylpropyl]-2,5-piperazinedione and acid addition salts thereof; pre-term labour, dysmenorrhea, endometriosis and benign prostatic hyperplasia, sexual disorders, fertility in farm animals
06/23/2009US7550461 Benzofuran and benzothiophene compounds useful in treating cytokine mediated diseases
06/23/2009US7550460 2,4-pyrimidinediamine compounds and their uses
06/23/2009US7550459 Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one
06/23/2009US7550458 Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
06/23/2009US7550457 Therapy of vascular system diseases
06/23/2009US7550455 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
06/23/2009US7550454 Analogs of clozapine; use with other neuropsychiatric agents; depression, anxiety, bipolar disorder, psychoses secondary to Alzheimer's or Huntington's disease; e.g. 2,7-Dichloro-11-(piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
06/23/2009US7550453 Anticancer agents; colon cancer or hepatocellular carcinoma; analogs of bengamide where the caprolactam ring is changed and/or substituted e.g. N-(2-Methyl-3-oxo-2,3,4,5-tetrahydro-1H-2-benzazepin-4-yl)-(E)-(2R,3R,4S,5R)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide
06/23/2009US7550452 N-Cholesteryloxyethylammonium (or amine) salt derivatives; compatible to gene therapy due to stability and highly transporting effects; drug delivery
06/23/2009US7550451 Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy
06/23/2009US7550450 Prostate cancer treatment
06/23/2009US7550449 4-(alkylcarbonyloxymethyl)-2-oxo-2-methoxy-1,2-oxaphospholane; anticancer, antimetastasis agents
06/23/2009US7550448 Therapeutic compounds
06/23/2009US7550447 Method for precipitating nucleic acid with visible carrier
06/23/2009US7550446 Modified hydroxyethyl- or hydroxypropyl-substituted starch product for clinical use, which has a degree of branching of 8-10 mol %, a degree of substitution of up to 0.3, an average molecular weight of 10000- 450000; product is not derived from an amylopectin fraction
06/23/2009US7550445 Inclusion complex in a beta-cyclodextrin, preferably, sulfobutyl ether beta-cyclodextrin, in the form of an injectable material; reducing irritation normally caused by aripiprazole at an intramuscular injection site; for treating schizophrenia
06/23/2009US7550444 Coatings with heparin activity, some able to release a bioactive agent; coatings can be formed using biostable or biodegradable polymeric material and photoreactive groups; improving the quality of bioactive agent-containing coatings by performing pre-irradiation of biocompatible coatings
06/23/2009US7550443 prosthesis, stent medical device has a multilayer with bioactive agent-releasing coatings having heparin activity; coatings are formed using biostable or biodegradable polymeric material and photoreactive groups; absorbs light at different wavelength, without hurting the bioactive agent
06/23/2009US7550442 For therapy of subject infected with a retrovirus
06/23/2009US7550441 Controlled release polymer nanoparticle containing bound nucleic acid ligand for targeting
06/23/2009US7550440 aqueous emulsion for the treatment of rosacea skin disorders, acne, dermatitis; Glycerol, Isopropyl palmitate, Cetyl alcohol, Stearyl monostearate, Oleyl alcohol, Ceteareth-20; good cosmetic properties and long shelf-life with minimum of 2 years
06/23/2009US7550432 Recombinant fusion proteins to growth hormone and serum albumin
06/23/2009US7550424 aromatic and heterocyclic sulfonamides, to treat preneoplastic and/or neoplastic diseases by specifically inhibiting the carbonic anhydrase activity of the oncoprotein now known alternatively as the MN protein, the MN/CA IX isoenzyme
06/23/2009US7550160 Composition for treating cancer cells and preparation method for the same
06/23/2009US7550159 For treatment of cancer and autoimmune diseases; kits
06/23/2009US7550157 Method for the preparation of polymeric micelle via phase separation of block copolymer
06/23/2009US7550155 two excipients are: a block co-polymer (for example, a poloxamer ), and a polyethylene glycol (PEG); with this synergistic mixture it is possible to dissolve or suspend higher amounts of propofol and other lipophilic compounds while, at the same time, using smaller amounts of these excipients
06/23/2009US7550153 Pantoprazole multiparticulate formulations
06/23/2009US7550146 Mucin motif found on epithelial tumor cell surfaces; antibody induction; cancer treatment
06/23/2009US7550145 Adjuvant compositions
06/23/2009US7550140 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy
06/23/2009US7550135 Composition for external application
06/23/2009US7550134 fluorene moiety attached to polymer backbone such as derived from an octadecene-maleic anhydride copolymer through a neopentyl glycol tether; stabilizing dibenzoylmethane compounds in sunscreens; waterproofing surfaces
06/23/2009US7550133 comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc
06/23/2009US7549424 Method and apparatus for tissue treatment with laser and electromagnetic radiation
06/23/2009CA2551963C Pharmaceutical compositions and treatment of arteriosclerosis with cs-866
06/23/2009CA2535920C Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
06/23/2009CA2522220C Cgrp receptor antagonists
06/23/2009CA2521509C Fast dissolving orally consumable films containing pharmaceutically active agents
06/23/2009CA2504735C Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
06/23/2009CA2492804C Novel inhibitors of kinases
06/23/2009CA2459483C Plaster for the treatment of dysfunctions and disorders of nail growth
06/23/2009CA2453917C Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient